Kalaris Therapeutics Reports Positive Expanded TH103 Phase 1a Data in Neovascular AMD
Kalaris Therapeutics released additional data from the expanded Phase 1a single ascending dose trial of TH103 in treatment-naive patients with neovascular age-related macular degeneration, with 20 patients completing six months of follow-up. The results build on earlier reported findings on vision, retinal anatomy and time to retreatment, but the filing covers an early-stage trial with small cohorts and includes no financial figures. The company said its Phase 1b/2 study remains on track to share initial data in the first half of 2027.
Key points
- Expanded dataset includes 17 treatment-naive patients and 3 treatment-experienced patients; all 20 completed six months of follow-up.
- Mean 9.2-letter best corrected visual acuity improvement at one month after a single TH103 injection in treatment-naive patients.
- 41% of treatment-naive patients (N=17) received a first retreatment at four months or later; 29% received no additional anti-VEGF treatment during six months.
- No intraocular inflammation among six patients at the 2.5 mg dose; one patient at the 5 mg dose had transient IOI that resolved without sequelae.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 17, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.